Massive companies handling prescriptions for millions of Americans will soon need to reveal detailed financial information under a new Trump administration regulation.
New Regulation Overview
The Labor Department’s rule mandates that pharmacy benefit managers disclose their financial interactions with drugmakers. This regulation aligns with President Trump’s efforts to lower drug prices and increase transparency in healthcare.
Labor Secretary Keith Sonderling stated that the administration aims to ensure price transparency across the healthcare industry. Employers can use this data to negotiate better deals and reduce drug prices for Americans on self-insured group healthcare plans, expected to impact over 72 million people.
Criticism and Response
Advocates and lawmakers have criticized pharmacy benefit managers for exploiting a lack of transparency to favor more expensive drugs. Despite this, major players like Express Scripts, Caremark, and Optum Rx, which control a large share of U.S. prescription drug claims, have pushed back against the rule.
A report from the Groundwork Collaborative highlighted the dominance of these companies, leading to calls for greater transparency.
Implementation Timeline
The regulation will take effect for healthcare plans starting in July. The overarching goal is to foster competition and benefit consumers with lower drug costs.